Brainsway (NASDAQ:BWAY) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says

Key Points

• LADENBURG THALM/SH SH raised Brainsway’s price target to $18.80 from $18.00 and maintained a “buy” rating, implying 12.54% upside from the prior close. Analysts overall maintain a “Moderate Buy” consensus, with six Buy ratings and one Hold.
• Brainsway reported quarterly EPS of $0.14, beating the $0.10 estimate, while revenue of $17.11 million exceeded the $16.54 million consensus. The company also forecast full-year 2026 revenue of $68 million to $70 million.
• BWAY shares rose 0.6% to $16.70 and are near their 52-week high of $17.40. Institutional investors own 30.11% of the stock, though Zacks Research recently downgraded it from “strong buy” to “hold.”

Brainsway (NASDAQ:BWAY - Get Free Report) had its price target raised by equities research analysts at LADENBURG THALM/SH SH from $18.00 to $18.80 in a research note issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. LADENBURG THALM/SH SH's price objective would indicate a potential upside of 12.54% from the company's previous close.

A number of other brokerages have also recently issued reports on BWAY. Zacks Research cut Brainsway from a "strong-buy" rating to a "hold" rating in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of Brainsway in a report on Friday, July 17th. New Street Research reiterated a "buy" rating on shares of Brainsway in a research report on Friday, July 24th. BTIG Research lifted their price target on shares of Brainsway from $18.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Weiss Ratings restated a "buy (b-)" rating on shares of Brainsway in a research report on Tuesday, July 21st. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $16.95.

Brainsway Trading Up 0.6%

BWAY traded up $0.10 on Thursday, hitting $16.70. 160,956 shares of the stock traded hands, compared to its average volume of 165,856. Brainsway has a 52 week low of $6.26 and a 52 week high of $17.40. The firm has a market capitalization of $670.37 million, a PE ratio of 48.02 and a beta of 1.24. The business has a fifty day moving average price of $15.08 and a two-hundred day moving average price of $14.33.

Brainsway (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. The company had revenue of $17.11 million during the quarter, compared to analysts' expectations of $16.54 million. On average, equities research analysts forecast that Brainsway will post 0.33 EPS for the current fiscal year.

Institutional Trading of Brainsway

Several institutional investors and hedge funds have recently added to or reduced their stakes in BWAY. Masters Capital Management LLC grew its holdings in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company's stock worth $21,928,000 after acquiring an additional 650,000 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company's stock valued at $6,890,000 after buying an additional 241,560 shares during the period. Sei Investments Co. lifted its holdings in Brainsway by 262.5% during the first quarter. Sei Investments Co. now owns 226,378 shares of the company's stock worth $3,009,000 after acquiring an additional 163,925 shares in the last quarter. Y.D. More Investments Ltd lifted its holdings in shares of Brainsway by 136.6% during the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company's stock valued at $3,615,000 after purchasing an additional 157,042 shares in the last quarter. Finally, ARK Investment Management LLC bought a new position in shares of Brainsway during the 4th quarter valued at about $2,422,000. 30.11% of the stock is owned by institutional investors.

More Brainsway News

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: BrainsWay reported second-quarter 2026 revenue of $17.1 million, up 35% year over year and ahead of the $16.54 million analyst consensus. Adjusted EPS of $0.14 also exceeded expectations of $0.10, reinforcing the company’s improving profitability. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Management issued fiscal 2026 revenue guidance of $68 million to $70 million, slightly above the $67.8 million consensus estimate. The guidance suggests continued demand and gives investors greater confidence in the company’s growth outlook.
• Positive Sentiment: BTIG Research raised its price target to $20 from $18 and maintained a “buy” rating, implying additional upside from recent trading levels. BTIG Raises BrainsWay Price Target
• Positive Sentiment: The earnings beat and growth outlook helped BWAY set a new one-year high, indicating strong investor momentum following the results. Brainsway Sets New One-Year High Following Strong Earnings
• Neutral Sentiment: BrainsWay’s earnings call provided additional details on its second-quarter performance and outlook. BrainsWay Q2 2026 Earnings Call Transcript
• Negative Sentiment: Zacks Research downgraded BWAY from “strong buy” to “hold.” The call is a more cautious signal after the recent rally and could weigh on near-term upside, despite the company’s strong fundamentals. Zacks Research

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source